A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Plaque Psoriasis

Treatments: Drug: Apremilast; Drug: Deucravacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT06382987

IM011-1124

Details and patient eligibility

About

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese adult participants aged 18 years old or older
• Physician-reported diagnosis of plaque psoriasis
• Newly initiating deucravacitinib or apremilast according to the label
• Participants who have signed informed consent

Exclusion criteria

• Participants currently participating in or planning to participate in an interventional clinical trial
• Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264)
• Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)

Trial design

600 participants in 2 patient groups

Participants that have initiated deucravacitinib treatment

Treatment:

Drug: Deucravacitinib

Participants that have initiated apremilast treatment

Treatment:

Drug: Apremilast